Scholarlink

Objective <p>This pilot study aimed to evaluate whether urine lipoarabinomannan (LAM) testing can be used to monitor tuberculosis treatment response in people living with HIV.</p> Results <p>Seventy-five participants were enrolled, of whom 51 (68%) were women, and 43 (57.4%) were antiretroviral therapy naïve. CD4 cell counts were available for 49 participants with a median of 58 cells/mm<sup>3</sup> (Interquartile range: 22–175). All participants initially tested positive for urine LAM; however, 12 (16%) converted to negative within two days of starting tuberculosis treatment. During the eight-week follow-up, 49 participants (65.3%) reverted from negative to positive at least once, primarily within the first two weeks, with notable peaks on day 4 (14, 28.6%) and day 5 (10, 20.4%). Of the 53 participants with urine LAM results at eight weeks, 26 participants (49.1%) had sustained urine LAM negativity. There was a significant LAM negativity trend from baseline to week 8 (Cochran-Armitage test for trend, <i>p</i> = 0.002). Urine LAM negativity did not significantly correlate with sputum smear or culture negativity (<i>p</i> = 0.521). These findings indicate that urine lipoarabinomannan testing is unreliable for monitoring tuberculosis treatment in people living with HIV, although repeated measurements offer insight into its performance in real-world settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The utility of urine lipoarabinomannan as a tuberculosis treatment monitoring tool in people living with HIV

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月8日

查看全文
  • Brian Otaalo,
  • Joseph Musaazi,
  • Ruth Nabisere-Arinaitwe,
  • Shakira Babirye,
  • Derek J. Sloan,
  • Willy Ssengooba,
  • Lydia Nakiyingi,
  • Steven J Reynolds,
  • Barbara Castelnuovo,
  • Yukari C. Manabe,
  • Christine Sekaggya-Wiltshire

摘要

Objective

This pilot study aimed to evaluate whether urine lipoarabinomannan (LAM) testing can be used to monitor tuberculosis treatment response in people living with HIV.

Results

Seventy-five participants were enrolled, of whom 51 (68%) were women, and 43 (57.4%) were antiretroviral therapy naïve. CD4 cell counts were available for 49 participants with a median of 58 cells/mm3 (Interquartile range: 22–175). All participants initially tested positive for urine LAM; however, 12 (16%) converted to negative within two days of starting tuberculosis treatment. During the eight-week follow-up, 49 participants (65.3%) reverted from negative to positive at least once, primarily within the first two weeks, with notable peaks on day 4 (14, 28.6%) and day 5 (10, 20.4%). Of the 53 participants with urine LAM results at eight weeks, 26 participants (49.1%) had sustained urine LAM negativity. There was a significant LAM negativity trend from baseline to week 8 (Cochran-Armitage test for trend, p = 0.002). Urine LAM negativity did not significantly correlate with sputum smear or culture negativity (p = 0.521). These findings indicate that urine lipoarabinomannan testing is unreliable for monitoring tuberculosis treatment in people living with HIV, although repeated measurements offer insight into its performance in real-world settings.